13 December 2021
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
13 December 2021
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
30 September 2021
Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption
29 September 2021
Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets
16 September 2021
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation
02 September 2021
Acacia Pharma to Host Webinar with Key Opinion Leaders to Discuss the Hospital User Experience with Barhemsys® and Byfavo®
29 June 2021
Results of Annual General Meeting
04 May 2021
Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital
21 April 2021
Acacia Pharma Becomes New Industry Supporter of the American Society of Anesthesiologists
30 March 2021
Publication of Annual Report and Financial Statements for the Year ended 31 December 2020
29 March 2021
Results for the Year ended 31 December 2020
18 February 2021
Change of EU Home Member State